Clinical Trial

CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-05-10; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2026-03-17
Trial Details
NCT Number NCT04881838
Lead Sponsor Children's Cancer Group, China
Collaborators: Shanghai Children's Medical Center, Nanjing Children's Hospital, Qilu Hospital of Shandong University, Tianjin Cancer Hospital, West China Second University Hospital, Xiangya Hospital, The First Affiliated Hospital of Zhengzhou University, Shenzhen Children's Hospital, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Conditions Pediatric Anaplastic Large Cell Lymphoma
Enrollment 172 participants
Start Date 2021-03-01
Primary Completion 2026-03-01 (estimated)
Study Completion 2029-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-19